tiprankstipranks
PaySign Inc Class B (PAYS)
NASDAQ:PAYS
US Market
Want to see PAYS full AI Analyst Report?

PaySign (PAYS) Earnings Dates, Call Summary & Reports

1,134 Followers

Earnings Data

Report Date
Aug 11, 2026
After Close (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
0.06
Last Year’s EPS
0.02
Same Quarter Last Year
Based on 4 Analysts Ratings

Earnings Call Summary

Q1 2026
Earnings Call Date:May 12, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call highlighted a very strong quarter: substantial revenue and profit growth, wide margin expansion, a robust pharma pipeline, and continued plasma revenue expansion and cash generation. Management reiterated confident full-year guidance and plans to exceed prior program-addition performance. Key risks discussed include a lower-than-guided plasma center count (due to sales/closures), the SaaS/app not yet producing revenue (FDA engagement ongoing), a higher effective tax rate, and margin variability driven by seasonal mix. Overall the positives (large percentage growth across revenue, EBITDA, operating margin, patient assistance dollars, and pipeline strength) substantially outweigh the operational and timing-related lowlights.
Company Guidance
Paysign reiterated full‑year 2026 targets of $106.5M–$110.5M in revenue (≈30%–35% YoY growth) with gross profit margins of 60%–62%, net income of $13M–$16M (≈$0.21–$0.26 per diluted share), and adjusted EBITDA of $30M–$33M (≈$0.49–$0.53 per diluted share); those outlooks follow a strong Q1 that produced $28.0M revenue (↑50.8% YoY; above prior guidance of $27.0M–$27.5M), $5.4M net income ($0.09/share), $10.6M adjusted EBITDA ($0.17/share) and expanded margins (gross margin 65%, operating margin 23.8%, adjusted EBITDA margin 37.8%); management expects to exit the quarter with 147–150 active patient affordability programs (141 today, 135 at quarter end, targeting >55 net program adds in 2026), patient affordability revenue of $15.7M in Q1 (↑81.9% YoY), plasma revenue of $11.7M in Q1 (↑24.9% YoY) with 573 centers at quarter end and an expected 555–560 centers after recent closures, $20.5M unrestricted cash (plus $159M restricted), zero bank debt, a Q1 effective tax rate of 27.2%, and a diluted share count of ~61M used for per‑share guidance.
Record Revenue Growth
Total revenue grew 50.8% year-over-year to $28.0 million, above the high end of guidance ($27.0 - $27.5M). Full-year revenue guidance is $106.5M-$110.5M (30%-35% YoY growth).
Strong Profitability & Operating Leverage
Net income increased 110% to $5.4 million ($0.09 per diluted share). Operating margin expanded ~1,040 basis points to 23.8% (from 13.4%), and adjusted EBITDA increased 113.4% to $10.6 million with adjusted EBITDA margin up to 37.8% (from 26.7%).
Patient Affordability (Pharma) Momentum
Pharma/patient affordability revenue rose 81.9% to $15.7 million; claim volume ~49% higher than Q1 2025. Patient affordability deployed >$540 million in financial assistance in Q1 vs ~$320 million a year ago. Active pharma programs grew (exited quarter at 135, 141 active at call, expected 147-150 by quarter end).
Plasma Business Growth and Cash Generation
Plasma revenue increased 24.9% year-over-year to $11.7 million. Average monthly revenue per center rose to $6,671 from $6,517. Exited quarter with 573 centers (up 89 year-over-year) and the plasma business remains a strong source of cash; unrestricted cash $20.5M and no bank debt.
Gross Margin Expansion
Gross profit margin expanded to 65% from 62.9% YoY, reflecting a higher mix of higher-margin Pharma revenue.
Efficient Expense Growth
Cost of revenues increased 42.2% and total operating expenses rose 25.5% (to $11.6M), both growing well below revenue growth, demonstrating operating leverage.
Robust Pipeline & Business Development
Management reported a strong pipeline after Assembia (ASX 26) with >50 meetings and real-time deal wins; they expect to exceed the 55 net program adds achieved in 2025, with roughly a 50/50 split between new clients and expansions.
Conservative Balance Sheet & Customer Deposits
Restricted cash increased to $159M (primarily customer program deposits and funds on card), and management holds substantial cash for potential acquisitions, shareholder returns, or other uses; remaining acquisition cash obligation is ~$6M to Gamma over next three anniversaries.

PaySign (PAYS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

PAYS Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 11, 2026
2026 (Q2)
0.06 / -
0.02
May 12, 2026
2026 (Q1)
0.07 / 0.09
0.0580.00% (+0.04)
Mar 24, 2026
2025 (Q4)
0.02 / 0.02
0.020.00% (0.00)
Nov 12, 2025
2025 (Q3)
0.02 / 0.04
0.0333.33% (+0.01)
Aug 05, 2025
2025 (Q2)
0.04 / 0.02
0.01100.00% (+0.01)
May 08, 2025
2025 (Q1)
0.02 / 0.05
0.01400.00% (+0.04)
Mar 25, 2025
2024 (Q4)
0.02 / 0.02
0.1-80.00% (-0.08)
Nov 05, 2024
2024 (Q3)
0.01 / 0.03
0.0250.00% (<+0.01)
Jul 31, 2024
2024 (Q2)
0.01 / 0.01
0
May 07, 2024
2024 (Q1)
0.00 / 0.01
0
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

PAYS Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 12, 2026
$6.65$5.83-12.33%
Mar 24, 2026
$3.77$5.15+36.60%
Nov 12, 2025
$5.47$5.470.00%
Aug 05, 2025
$7.12$5.22-26.69%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does PaySign Inc Class B (PAYS) report earnings?
PaySign Inc Class B (PAYS) is schdueled to report earning on Aug 11, 2026, After Close (Confirmed).
    What is PaySign Inc Class B (PAYS) earnings time?
    PaySign Inc Class B (PAYS) earnings time is at Aug 11, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is PAYS EPS forecast?
          PAYS EPS forecast for the fiscal quarter 2026 (Q2) is 0.06.